Your browser doesn't support javascript.
A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy.
Kamegai, Kohei; Iwamoto, Noriko; Togano, Tomiteru; Maeda, Kenji; Takamatsu, Yuki; Miyazato, Yusuke; Ishikane, Masahiro; Mizokami, Masashi; Sugiyama, Masaya; Iida, Shun; Miyamoto, Sho; Suzuki, Tadaki; Ohmagari, Norio.
  • Kamegai K; National Center for Global Health and Medicine, Tokyo, Japan.
  • Iwamoto N; National Center for Global Health and Medicine, Tokyo, Japan. Electronic address: nkinoshita@hosp.ncgm.go.jp.
  • Togano T; National Center for Global Health and Medicine, Tokyo, Japan.
  • Maeda K; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute.
  • Takamatsu Y; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute.
  • Miyazato Y; National Center for Global Health and Medicine, Tokyo, Japan.
  • Ishikane M; National Center for Global Health and Medicine, Tokyo, Japan.
  • Mizokami M; National Center for Global Health and Medicine, Tokyo, Japan.
  • Sugiyama M; National Center for Global Health and Medicine, Tokyo, Japan.
  • Iida S; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Miyamoto S; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Suzuki T; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Ohmagari N; National Center for Global Health and Medicine, Tokyo, Japan.
Int J Infect Dis ; 121: 85-88, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1873077
ABSTRACT
Although messenger ribonucleic acid vaccines are substantially effective toward SARS-CoV-2 infection, patients with hematologic malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 Delta variant infection in a patient with mucosa-associated lymphoid tissue lymphoma with remission by bendamustine-rituximab (BR) therapy completed a year ago. The serologic study revealed impaired responsiveness toward vaccines and prolonged high viral load after infection. BR therapy seemingly induced an immune escape. Prevention and treatment strategies for such vulnerable patients should be clarified immediately.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Case report Topics: Vaccines / Variants Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: J.ijid.2022.04.058

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Case report Topics: Vaccines / Variants Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: J.ijid.2022.04.058